

Supporting Information

Rec. Nat. Prod. 17:4 (2023) 705-709

A New Megastigmane Glycoside And Anti-Inflammatory Bibenzyls And From The Stems of *Dendrobium henanense*

Siyu Wu¹, Shihui Qin¹, Chuihao Kong¹, Renzhong Wang^{1*}, Deling Wu^{1,2}
and Fengqing Xu^{1,2*}

¹Department of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P. R. China

²Anhui Province Key Laboratory of New Manufacturing Technology for Traditional Chinese Medicine
Decoction Pieces, Hefei 230012, P. R. China

³Anhui Province Key Laboratory of Research and Development of Chinese Medicine, Hefei 230012,

P. R.China

Table of Contents	Page
Figure S1: ESI-MS Spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	3
Figure S2: HR-ESI-MS spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	3
Figure S3: ¹ H-NMR (400 MHz, CD ₃ OD) spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	4
Figure S4: ¹³ C-NMR (150 MHz, CD ₃ OD) spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	5
Figure S5: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	6
Figure S6: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 0.6 ppm to δ_H 2.3 ppm)	7
Figure S7: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 1.44 ppm to δ_H 1.88 ppm)	8
Figure S8: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 2.0 ppm to δ_H 2.9 ppm)	9
Figure S9: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 3.76 ppm to δ_H 3.98 ppm)	10
Figure S10: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 3.02 ppm to δ_H 3.36 ppm)	11
Figure S11: HSQC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 3.6 ppm to δ_H 8.2 ppm)	12
Figure S12: HMBC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one)	13
Figure S13: HMBC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 5.2 ppm to δ_H 7.4 ppm)	14
Figure S14: HMBC spectrum of 1 ((9 <i>S</i>)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 4.12 ppm to δ_H 4.64 ppm)	15

Figure S15: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.72 ppm to δ_{H} 4.12 ppm)	16
Figure S16: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.48 ppm to δ_{H} 3.72 ppm)	17
Figure S17: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.15 ppm to δ_{H} 3.39 ppm)	18
Figure S18: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 2.15 ppm to δ_{H} 2.85 ppm)	19
Figure S19: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.80 ppm to δ_{H} 2.01 ppm)	20
Figure S20: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.60 ppm to δ_{H} 1.77 ppm)	21
Figure S21: HMBC spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 0.98 ppm to δ_{H} 1.38 ppm)	22
Figure S22: ^1H - ^1H COSY spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	23
Figure S23: ^1H - ^1H COSY spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 5.2 ppm to δ_{H} 8.0 ppm)	24
Figure S24: ^1H - ^1H COSY spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 0.2 ppm to δ_{H} 5.8 ppm)	25
Figure S25: ^1H - ^1H COSY spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.5 ppm to δ_{H} 2.7 ppm)	26
Figure S26: ROESY spectrum of 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	27
Figure S27: The HPLC of sugar in compound 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	28
Figure S28: The circular dichroism spectrum of compound 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	29
Figure S29: Calculated and experimental ECD spectra of compound 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	29
Figure S30: Similarity report of compound 1 ((9 <i>S</i>)- <i>O</i> - β -D-glucopyranosyl-2,5-megastigmen-4-one)	30-31





Figure S1: ESI-MS Spectrum of 1 ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4- one)

User Spectra



Peak List

<i>m/z</i>	<i>z</i>	Abund	Formula	Ion
112.9855	1	16070.53		
369.1924	1	71310.68	C19 H30 O7	(M-H)-
405.1689	1	22914.64		
415.1981	1	83379.62		
416.2011	1	18338.2		
432.1879	1	15022.06		
483.1858	1	149955.14		
484.1889	1	34733.03		
739.3917	1	40807.55		
740.3954	1	17841.75		

Formula Calculator Element Limits

Element	Min	Max
C	3	120
H	0	300
O	0	30

Formula Calculator Results

Formula	CalculatedMass	CalculatedMz	Mz	Diff. (mDa)	Diff. (ppm)	DBE
C19 H30 O7	370.1992	369.1919	369.1924	-0.50	-1.35	5.0000

Figure S2: HR-ESI-MS Spectrum of 1 ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4- one)




Figure S3: $^1\text{H-NMR}$ (400 MHz, CD_3OD) Spectrum of **1** (((*9S*)-*O*- β -*D*-glucopyranosyl-2,5-megastigmen-4-one)




Figure S4: ^{13}C -NMR (150 MHz, CD_3OD) Spectrum of **1** ((*9S*)-*O*- β -*D*-glucopyranosyl-2,5-megastigmen-4-one)




Figure S5: HSQC Spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4- one)




Figure S6: HSQC spectrum of **1** ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 0.6 ppm to δ_{H} 2.3 ppm)




Figure S7: HSQC spectrum of **1** ((9S)-O-β-D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.44 ppm to δ_{H} 1.88 ppm)




Figure S8: HSQC spectrum of **1** ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 2.0 ppm to δ_H 2.9 ppm)




Figure S9: HSQC spectrum of **1** ((9S)-O-β-D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.76 ppm to δ_{H} 3.98 ppm)




Figure S10: HSQC spectrum of **1** ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.02 ppm to δ_{H} 3.36 ppm)




Figure S11: HSQC spectrum of **1** ((9S)-O- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.6 ppm to δ_{H} 8.2 ppm)




Figure S12: HMBC Spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one)




Figure S13: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 5.2 ppm to δ_H 7.4 ppm)




Figure S14: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 4.12 ppm to δ_{H} 4.64 ppm)




Figure S15: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_H 3.72 ppm to δ_H 4.12 ppm)




Figure S16: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.48 ppm to δ_{H} 3.72 ppm)




Figure S17: HMBC spectrum of **1** ((*9S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 3.15 ppm to δ_{H} 3.39 ppm)




Figure S18: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4- one) (From δ_H 2.15 ppm to δ_H 2.85 ppm)




Figure S19: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.80 ppm to δ_{H} 2.01 ppm)




Figure S20: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.60 ppm to δ_{H} 1.77 ppm)




Figure S21: HMBC spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4- one) (From δ_H 0.98 ppm to δ_H 1.38 ppm)




Figure S22: ^1H - ^1H COSY Spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4- one)




Figure S23: ^1H - ^1H COSY Spectrum of **1** ((*9S*)-*O*- β -*D*-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 5.2 ppm to δ_{H} 8.0 ppm)




Figure S24: ^1H - ^1H COSY Spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4- one) (From δ_{H} 0.2 ppm to δ_{H} 5.8 ppm)




Figure S25: ^1H - ^1H COSY Spectrum of **1** ((9*S*)-*O*- β -D-glucopyranosyl-2,5-megastigmen-4-one) (From δ_{H} 1.5 ppm to δ_{H} 2.7 ppm)





Figure S26: ROESY spectrum of **1** ((9*S*)-O- β -D-glucopyranosyl-2,5-megastigmen-4- one)



a hydrolysis experiment to determine the absolute configuration of sugar moiety in **1**.

Compound **1** was acid hydrolyzed according to the method described in the literature. Compound **1** (3 mg) was individually refluxed with 5 % HCl in MeOH (5 mL) for 2 hrs. The solution was diluted with H₂O (5 mL) and extracted with EtOAc (10 mL) for 3 times. The aqueous layer was neutralized with NaHCO₃ and concentrated in vacuum to give a residue. Purification of the residue was performed by RP-18 column, eluted with 20% MeOH-H₂O, to afford the purified sugar. The optical rotation was determined after dissolving the sugar in MeOH: $[\alpha]_{22.3}^D$: +40.1 (c 0.09, MeOH). And the sugar molecule were determined to be D-glc using HPLC-CAD, in contrast with the reference D-glc. Chromatographic analyses were performed on a Uimate 3000 HPLC system equipped with a CAD detector. Chromatographic separation was carried out at 30 °C on a Shodex Asahipak NH₂-P-50 4E column (250 mm × 4.6 mm, 5 μm, USA). The mobile phase was composed of acetonitrile-water (25 : 75, v/v) at 1.0 ml·min⁻¹, every 3 μL sample solution was injected for each run and the CAD spectra were recorded at the frequency was 5 Hz, the filter was 3.6F, the atomizer temperature was 35 °C, the air source was N₂, and the pressure was 4.328×10⁵ Pa.

Figure S27: The HPLC of sugar in compound **1** ((9*S*)-O-β-D-glucopyranosyl-2,5-megastigmen-4-one)




Figure S28: The circular dichroism spectrum of compound **1** ((*9S*)-*O*- β -*D*-glucopyranosyl-2,5-megastigmen-4-one)




Figure S29: Calculated and experimental ECD spectra of compound **1**((*9S*)-*O*- β -*D*-glucopyranosyl-2,5-megastigmen-4-one)

Figure S30: Similarity report of compound 1((9S)-O-β-D-glucopyranosyl-2,5-megastigmen-4- one)



Figure S30: Similarity report of compound 1((9S)-O-β-D-glucopyranosyl-2,5-megastigmen-4-one)

